The hurdles of nanotoxicity in transplant nanomedicine

In this review, researchers from the Office of Science & Technology (TX, USA) evaluate the toxicological profiles of immunosuppressant therapies and their conversion into nanomedicine formulations.

Nanomedicine has matured significantly in the past 20 years and a number of nanoformulated therapies are cleared by regulatory agencies for use across the globe. Transplant medicine is one area that has significantly benefited from the advancement of nanomedicine in recent times. However, while nanoparticle-based therapies have improved toxicological profiles of some drugs, there are still a number of aspects regarding the biocompatibility and toxicity of nanotherapies that require further research.

In this review, researchers from the Office of Science & Technology (TX, USA) evaluate the toxicological profiles of immunosuppressant therapies and their conversion into nanomedicine formulations, as well as introduce future challenges associated with current in vitro and in vivo toxicological models.